Brokerages Set Delcath Systems, Inc. (NASDAQ:DCTH) Price Target at $18.50

Delcath Systems, Inc. (NASDAQ:DCTHGet Free Report) has been given a consensus rating of “Buy” by the five research firms that are presently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have covered the stock in the last year is $20.20.

A number of equities analysts have commented on the company. HC Wainwright lifted their price target on Delcath Systems from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, May 15th. upgraded shares of Delcath Systems to a “sell” rating in a report on Wednesday, March 27th. Finally, Stephens initiated coverage on shares of Delcath Systems in a research report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 price target for the company.

Read Our Latest Analysis on Delcath Systems

Insiders Place Their Bets

In related news, Director Gil Aharon purchased 26,882 shares of Delcath Systems stock in a transaction that occurred on Tuesday, March 19th. The shares were bought at an average price of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the transaction, the director now directly owns 1,069,710 shares of the company’s stock, valued at $3,979,321.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 17.94% of the company’s stock.

Hedge Funds Weigh In On Delcath Systems

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vivo Capital LLC lifted its position in Delcath Systems by 57.4% during the 3rd quarter. Vivo Capital LLC now owns 1,855,191 shares of the company’s stock valued at $7,514,000 after acquiring an additional 676,404 shares during the period. BVF Inc. IL boosted its position in shares of Delcath Systems by 23.1% in the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock worth $5,734,000 after purchasing an additional 225,918 shares in the last quarter. AIGH Capital Management LLC purchased a new stake in shares of Delcath Systems in the 4th quarter worth approximately $4,918,000. Stonepine Capital Management LLC increased its position in Delcath Systems by 81.2% during the 3rd quarter. Stonepine Capital Management LLC now owns 686,240 shares of the company’s stock valued at $2,779,000 after buying an additional 307,453 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Delcath Systems by 31.0% during the first quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after buying an additional 161,678 shares during the last quarter. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Performance

Shares of DCTH opened at $8.03 on Tuesday. Delcath Systems has a fifty-two week low of $2.25 and a fifty-two week high of $8.18. The firm has a 50 day moving average price of $5.17 and a 200-day moving average price of $4.27. The firm has a market cap of $223.12 million, a price-to-earnings ratio of -3.03 and a beta of 0.55.

Delcath Systems (NASDAQ:DCTHGet Free Report) last posted its quarterly earnings results on Tuesday, March 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.19. The business had revenue of $0.54 million during the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative net margin of 1,080.72% and a negative return on equity of 290.07%. During the same period in the prior year, the business posted ($0.86) earnings per share. As a group, equities research analysts predict that Delcath Systems will post -1.25 earnings per share for the current year.

About Delcath Systems

(Get Free Report

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Read More

Analyst Recommendations for Delcath Systems (NASDAQ:DCTH)

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with's FREE daily email newsletter.